Physician profile
David A Denman
NPI 1942287453
$14,323.30
in general payments reported to CMS, 2019-2025
64 companies · $2,468 in 2025
The $2,468 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,734 · 2020: $1,012 · 2021: $2,560 · 2022: $2,877 · 2023: $1,769 · 2024: $1,904 · 2025: $2,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,127 · Entertainment: $13.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,127.10 |
| Entertainment | $13.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,935.30 | 2020-2025 | Creon, Qulipta, Ubrelvy |
| Pfizer INC. | $1,184.49 | 2019-2025 | |
| Novo Nordisk INC | $1,174.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $963.34 | 2019-2025 | Evenity, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $853.86 | 2022 | |
| Lilly USA, LLC | $660.24 | 2019-2025 | Mounjaro, Olumiant, Taltz |
| Glaxosmithkline, LLC. | $522.06 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $515.44 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $508.90 | 2019-2025 | Jardiance, Ofev |
| Regeneron Healthcare Solutions, INC. | $483.01 | 2024-2025 | Dupixent, Libtayo |
| Abbott Laboratories | $393.71 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $377.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $347.07 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.43 | 2019-2025 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $270.58 | 2023-2025 | Gemtesa |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Denman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.